silybin has been researched along with cryptotanshinone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Chen, H; Feng, N; He, Y; Hou, X; Liu, Y; Shen, J; Shi, J; Wang, Z; Xie, X | 1 |
2 other study(ies) available for silybin and cryptotanshinone
| Article | Year |
|---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis.
Topics: Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Caco-2 Cells; Cell Movement; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mucus; Nanoparticles; Neoplasms, Experimental; Phenanthrenes; Rats, Sprague-Dawley; Silybin; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |